Rapid Resolution of Life-Threatening Hypertriglyceridemia after Evinacumab Administration in a Pediatric HSCT Recipient: A Case Report

Evinacumab, a human monoclonal antibody against angiopoietin-like protein 3 (ANGPTL3), has recently been approved by the U.S. Food and Drug Administration as an add-on therapy for homozygous familial hypercholesterolemia (HoFH) in patients of 12 years and older. Its role as a triglyceride-lowering d...

Descripción completa

Detalles Bibliográficos
Autores principales: Fachin, Alice, De Carlo, Chiara, Maestro, Alessandra, Zanon, Davide, Barbi, Egidio, Maximova, Natalia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457918/
https://www.ncbi.nlm.nih.gov/pubmed/37630982
http://dx.doi.org/10.3390/ph16081069

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10457918/
https://www.ncbi.nlm.nih.gov/pubmed/37630982
http://dx.doi.org/10.3390/ph16081069

Ejemplares similares